Compounds that lower the threshold of calcium sensing receptors in the parathyroid gland by serum calcium.
Can reduce serum parathyroid hormone levels with normal or impaired renal function and in hyperparathyroidism.
Reduce parathyroid hormone, calcium and phosphorus levels in patients on hemodialysis.
Calcium receptor is a cell surface receptor expressed on parathyroid chief cells, myocardium, blood vessels, stomach, intestine and the kidneys, and helps maintain serum calcium within a narrow range.
Increased serum calcium decreases parathyroid secretion by the activation of the calcium receptor in the parathyroid gland and enhanced calciuria by the activation of the same receptor present in the ascending limb of the loop of Henle and distal nephron.
Bind to the calcium receptor resulting in a shift in the calcium response curve, over activation of the calcium receptor and decrease in parathyroid hormone secretion.
A calcimimetic therapy is a considered therapy for some patients with severe hypercalcemia and primary hyperparathyroidism who are unable to undergo parathyroidectomy and for secondary hyperparathyroidism on dialysis.
Calciminetics control PTH release from parathyroid glands without increasing calcium and phosphorus levels.
The most common side effects of calcimimetics are mild or moderate nausea and vomiting.
Cinacalcet brand name Sensipar is the only drug of this class.
Cinacalcet mimics calcium at the parathyroid hormone receptor